Already boasting the marketed Nubeqa, Orion licenses its next-biggest prostate cancer hope to Merck & Co.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
Results of the prostate cancer project’s pivotal Aramis trial, already known to be positive, are presented for the first time.
But Erleada, Johnson & Johnson’s next-gen prostate cancer therapy, still needs to outperform the incumbent, Zytiga.
Galapagos and Bayer/Orion will both report phase III data this quarter – the former with filgotinib in arthritis and the latter with darolutamide in prostate cancer.